“Pharmacological Clinical Trials for Multiple Sclerosis: A Review of Fluid Biomarker Use”

https://pubmed.ncbi.nlm.nih.gov/38117403

In a review of ongoing pharmacological clinical trials for Multiple Sclerosis, 5% of studies incorporated fluid biomarkers, primarily neurofilament light chains, to evaluate the effectiveness of approved and new drugs, although further validation and cost-effectiveness studies are required for clinical practice implementation.